VivoSeq
Other

Neurodevelopment

0

Pipeline Programs↗

6

Active Trials↗

1

Companies Involved↗

Neurodevelopment is an early-stage landscape with 0 programs across 1 company. The most active players are Shionogi.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Shionogi logo

Shionogi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

18

clinical trials

Completed9 · 50%
Unknown status3 · 17%
Recruiting2 · 11%
Active, not recruiting2 · 11%
Enrolling by invitation1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

18 trials

30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants
Recruiting·UUniversity of Alberta·N/A·NCT03825835·1,200 enrolled
Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome
Recruiting·CCTNNB1 Foundation·Phase 1/2·NCT07270549·12 enrolled
Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA)
Active, not recruiting·Nn-Lorem Foundation·Phase 1/2·NCT07197294·1 enrolled
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
Active, not recruiting·Shionogi logoShionogi·Phase 2·NCT06717438·30 enrolled
Micronutrient Enhancement for Development and Health in Adolescents
Not yet recruiting·JJohns Hopkins Bloomberg School of Public Health·Phase 3·NCT07695883·3,000 enrolled
Gene Therapy for SLC6A1 Neurodevelopmental Disorder
Enrolling by invitation·EEmily de los Reyes·Phase 1/2·NCT07173153·1 enrolled
Neurodevelopment After Early Iron Supplementation
Completed·UUniversity of Ulm·N/A·NCT00457990·204 enrolled
Iron Supplementation and Neurodevelopmental Outcome in ELGANs
Completed·—·Phase 3·NCT04691843·51 enrolled
The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)
Completed·SStanford University·N/A·NCT03882788·153 enrolled
MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine
Completed·WWashington University School of Medicine·Phase 4·NCT00809055·74 enrolled
Cerebrolysin and Neurodevelopment in Preterm Infants
Completed·MMansoura University Children Hospital·Phase 1·NCT03506841·60 enrolled
ASPIRIN: Neurodevelopmental Follow-up Trial
Completed·NNICHD Global Network for Women's and Children's Health·N/A·NCT04888377·666 enrolled
A Comparison of Two Different Doses of Maternal B12 Supplementation in Improving Infant B12 Deficiency and Neurodevelopment
Completed·SSitaram Bhartia Institute of Science and Research·N/A·NCT04083560·708 enrolled
Neurodevelopmental Impact of Treatment in Hypothyroxinaemia of Prematurity.
Completed·HHospices Civils de Lyon·N/A·NCT06346236·373 enrolled
Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
Completed·MMontefiore Medical Center·Phase 2/3·NCT01783041·144 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)